Lawrence Soon-U Lee

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9091462/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Severe Acute Respiratory Syndrome (SARS) in Singapore: Clinical Features of Index Patient and Initial Contacts. Emerging Infectious Diseases, 2003, 9, 713-717.	2.0	257
2	Hypocortisolism in survivors of severe acute respiratory syndrome (SARS). Clinical Endocrinology, 2005, 63, 197-202.	1.2	228
3	Chloroquine for influenza prevention: a randomised, double-blind, placebo controlled trial. Lancet Infectious Diseases, The, 2011, 11, 677-683.	4.6	162
4	Pulmonary function and exercise capacity in survivors of severe acute respiratory syndrome. European Respiratory Journal, 2004, 24, 436-442.	3.1	131
5	Quality of life and psychological status in survivors of severe acute respiratory syndrome at 3 months postdischarge. Journal of Psychosomatic Research, 2006, 60, 513-519.	1.2	105
6	1-Year Pulmonary Function and Health Status in Survivors of Severe Acute Respiratory Syndrome. Chest, 2005, 128, 1393-1400.	0.4	103
7	HIV/AIDS: Interactions between Natural Health Products and Antiretroviral Drugs: Pharmacokinetic and Pharmacodynamic Effects. Clinical Infectious Diseases, 2006, 43, 1052-1059.	2.9	89
8	Pharmacokinetics of prenylflavonoids and correlations with the dynamics of estrogen action in sera following ingestion of a standardized Epimedium extract. Journal of Pharmaceutical and Biomedical Analysis, 2009, 50, 216-223.	1.4	66
9	Safety and immunogenicity of a virus-like particle pandemic influenza A (H1N1) 2009 vaccine: Results from a double-blinded, randomized Phase I clinical trial in healthy Asian volunteers. Vaccine, 2014, 32, 5041-5048.	1.7	63
10	Differential Effects of Tipranavir plus Ritonavir on Atorvastatin or Rosuvastatin Pharmacokinetics in Healthy Volunteers. Antimicrobial Agents and Chemotherapy, 2009, 53, 4385-4392.	1.4	56
11	Population Pharmacokinetics of Polymyxin B. Clinical Pharmacology and Therapeutics, 2018, 104, 534-538.	2.3	55
12	A novel prenylflavone restricts breast cancer cell growth through AhR-mediated destabilization of ERα protein. Carcinogenesis, 2012, 33, 1089-1097.	1.3	46
13	Possible Differential Induction of Phase 2 Enzyme and Antioxidant Pathways by American Ginseng, <i>Panax quinquefolius</i> . Journal of Clinical Pharmacology, 2008, 48, 599-609.	1.0	40
14	Molecular and pharmacodynamic properties of estrogenic extracts from the traditional Chinese medicinal herb, Epimedium. Journal of Ethnopharmacology, 2007, 113, 218-224.	2.0	36
15	Population Pharmacokinetic Analysis of Isoniazid, Acetylisoniazid, and Isonicotinic Acid in Healthy Volunteers. Antimicrobial Agents and Chemotherapy, 2015, 59, 6791-6799.	1.4	36
16	Pharmacokinetic Modeling of Plasma and Intracellular Concentrations of Raltegravir in Healthy Volunteers. Antimicrobial Agents and Chemotherapy, 2011, 55, 4090-4095.	1.4	30
17	Preclinical pharmacokinetic studies of 3-deazaneplanocin A, a potent epigenetic anticancer agent, and its human pharmacokinetic prediction using GastroPlusâ"¢. European Journal of Pharmaceutical Sciences, 2015, 77, 290-302.	1.9	29
18	Population pharmacokinetics of rifampicin and 25-deacetyl-rifampicin in healthy Asian adults. Journal of Antimicrobial Chemotherapy, 2015, 70, 3298-3306.	1.3	24

#	Article	IF	CITATIONS
19	Development and validation of liquid chromatography tandem mass spectrometry method quantitative determination of polymyxin B1, polymyxin B2, polymyxin B3 and isoleucine-polymyxin B1 in human plasma and its application in clinical studies. Journal of Pharmaceutical and Biomedical Analysis, 2017, 140, 91-97.	1.4	20
20	Pharmacokinetics of ertapenem in outpatients with complicated urinary tract infections. Journal of Antimicrobial Chemotherapy, 2014, 69, 2517-2521.	1.3	19
21	(3R,9R,10R)-Panaxytriol: a molecular-based nutraceutical with possible application to cancer prevention and treatment. Tetrahedron Letters, 2008, 49, 7178-7179.	0.7	18
22	Bioassays for Estrogenic Activity: Development and Validation of Estrogen Receptor (ERα/ERβ) and Breast Cancer Proliferation Bioassays to Measure Serum Estrogenic Activity in Clinical Studies. Assay and Drug Development Technologies, 2009, 7, 80-89.	0.6	18
23	Activity of faropenem with and without rifampicin against Mycobacterium tuberculosis: evaluation in a whole-blood bactericidal activity trial. Journal of Antimicrobial Chemotherapy, 2017, 72, 2012-2019.	1.3	17
24	CYP3A5*3 and bilirubin predict midazolam population pharmacokinetics in Asian cancer patients. Journal of Clinical Pharmacology, 2014, 54, 215-224.	1.0	15
25	Adjunctive use of celecoxib with anti-tuberculosis drugs: evaluation in a whole-blood bactericidal activity model. Scientific Reports, 2018, 8, 13491.	1.6	15
26	Induction of Chemoprotective Phase 2 Enzymes by Ginseng and its Components. Planta Medica, 2009, 75, 1129-1133.	0.7	13
27	Simultaneous determination of raltegravir and raltegravir glucuronide in human plasma by liquid chromatography–tandem mass spectrometric method. Journal of Mass Spectrometry, 2011, 46, 202-208.	0.7	13
28	Therapeutic drug monitoring of meropenem and piperacillin-tazobactam in the Singapore critically ill population – A prospective, multi-center, observational study (BLAST 1). Journal of Critical Care, 2022, 68, 107-113.	1.0	13
29	Pharmacokinetics of Prenylflavonoids following Oral Ingestion of Standardized Epimedium Extract in Humans. Planta Medica, 2019, 85, 347-355.	0.7	12
30	Dynamics of progestogenic activity in serum following administration of Ligusticum chuanxiong. Life Sciences, 2006, 79, 1274-1280.	2.0	11
31	Darunavir/ritonavir and efavirenz exert differential effects on MRP1 transporter expression and function in healthy volunteers. Antiviral Therapy, 2010, 15, 275-279.	0.6	9
32	Pharmacokinetics of Darunavir at 900 Milligrams and Ritonavir at 100 Milligrams Once Daily when Coadministered with Efavirenz at 600 Milligrams Once Daily in Healthy Volunteers. Antimicrobial Agents and Chemotherapy, 2010, 54, 2775-2780.	1.4	9
33	Accelerator Mass Spectrometry Measurement of Intracellular Concentrations of Active Drug Metabolites in Human Target Cells In Vivo. Clinical Pharmacology and Therapeutics, 2010, 88, 796-800.	2.3	8
34	Strongyloides Hyperinfection Associated with Enterococcus faecalis Bacteremia, Meningitis, Ventriculitis and Gas-Forming Spondylodiscitis: A Case Report. Tropical Medicine and Infectious Disease, 2020, 5, 44.	0.9	8
35	Phenotyping of UGT1A1 Activity Using Raltegravir Predicts Pharmacokinetics and Toxicity of Irinotecan in FOLFIRI. PLoS ONE, 2016, 11, e0147681.	1.1	7
36	Pulmonary function and exercise capacity in survivors of Severe Acute Respiratory Syndrome. Chest, 2004, 126, 8685.	0.4	5

#	Article	IF	CITATIONS
37	Population Pharmacokinetics of Modafinil and Its Acid and Sulfone Metabolites in Chinese Males. Therapeutic Drug Monitoring, 2011, 33, 719-729.	1.0	4
38	Simultaneous determination of probe drugs, metabolites, inhibitors and inducer in human plasma by liquid chromatography/tandem mass spectrometry and its application to pharmacokinetic study. Journal of Pharmaceutical and Biomedical Analysis, 2014, 88, 584-593.	1.4	4
39	Pharmacokinetics of Indinavir at 800, 600, and 400 Milligrams Administered with Ritonavir at 100 Milligrams and Efavirenz in Ethnic Chinese Patients Infected with Human Immunodeficiency Virus. Antimicrobial Agents and Chemotherapy, 2004, 48, 4476-4478.	1.4	3
40	A Simple and Powerful Method for the Estimation of Intervention Effects on Serological Endpoints Using Paired Interval-Censored Data. Journal of Biopharmaceutical Statistics, 2015, 25, 124-136.	0.4	3
41	Infectious diseases in Singapore and Asia: persistent challenges in a new era. Singapore Medical Journal, 2017, 58, 169-170.	0.3	2
42	Correlation of pharmacokinetics of CPT-11 in FOLFIRI with phenotyping of CYP3A4 and UGT1A1 activity Journal of Clinical Oncology, 2012, 30, e13002-e13002.	0.8	0